This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Public session of the Cancer Drug Development Roundtable at Ohio State

April 25th, 2011

The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and Friends of Cancer Research (Friends) are convening a high-level group of stakeholders to discuss current obstacles halting co-development of two or more experimental drugs for the treatment of cancer.

In December 2010, the U.S. Food and Drug Administration (FDA) released a Guidance Document addressing the protocol researchers should follow when deciding if co-developing drugs is appropriate. However, barriers found outside of clinics and labs, such as business, legal, liability and intellectual property issues were not examined in detail.

The objective of the Cancer Drug Development Roundtable is to develop a set of recommendations for the FDA to be revealed later this year, addressing industry hurdles currently halting co-development, with the ultimate goal of easing the process and bringing revolutionary cancer treatments to patients faster and with more efficiency.

Prior to the closed working session occurring later in the day, Roundtable participants will hold an open public session for researchers, advocates, patients and media that would like to learn more about the issue and ask questions. Panel participants include:

Michael Caligiuri, M.D. - Director of The Ohio State Comprehensive Cancer Center and CEO of the James Cancer Hospital and Solove Research Institute
Jim Doroshow, M.D. - Director of the Division of Cancer Treatment and Diagnosis at the National Cancer Institute
Eric Rubin, M.D. - Vice President, Oncology Clinical Research, Merck
Ellen Sigal, Ph.D. - Chair and Founder, Friends of Cancer Research
Janet Woodcock, M.D. - Director, Center for Drug Evaluation and Research, FDA

WHERE: The Ohio State University, Biomedical Research Tower, Room 115, 460 W. 12th Avenue, Columbus, OH 43210

For those unable to attend in person, the Public Session will also be made available via Webcast and teleconference (Please RSVP to lbryan@spectrumscience.com for dial-in information and link).

WHEN: Wednesday, May 4, 2011

10:00 - 11:00 a.m.

WHO: Hosted by Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) and Friends of Cancer Research (Friends)

Provided by Ohio State University Medical Center

Citation: Public session of the Cancer Drug Development Roundtable at Ohio State (2011, April 25) retrieved 13 August 2026 from https://sciencex.com/wire-news/65202523/public-session-of-the-cancer-drug-development-roundtable-at-ohio.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.